Tumor genetic analysis (also known as genotyping) is becoming increasingly important for effectively tailoring cancer treatment based on specific genetic abnormalities found in an individual’s tumor. This information can guide the use of certain FDA-approved standard therapies, and can also help direct patients to the most relevant investigational drugs available in clinical trials. Options available for tumor molecular testing are rapidly expanding, some of which are listed below:
MGH Tumor Genotyping
The Massachusetts General Hospital was one of the first Cancer Centers to develop and offer tumor molecular testing that simultaneously screens for well over 100 cancer-associated mutations that have important clinical implications. This assay, known as MGH SNaPshot, is performed as a CLIA-validated clinical assay (not research) that can be ordered by any one of our treating oncologists. All patients seen in consultation at the MGH Cancer Center, regardless of cancer type, are considered for tumor testing using MGH SNaPshot if the results might contribute to their care.
To receive more information on MGH SNaPshot testing, please click to request a consultation
or call 617-726-0808
Commercial Testing Ordered Through Your Oncologist
Your current or local oncologist can order tumor genetic testing from a variety of commercial sources. Like MGH SNaPshot, this testing can be performed simply from the pathology diagnostic tissue specimen that was used in your original diagnosis. These test offerings primarily differ by the number of target genes and mutations evaluated, which is directly proportional to the cost and time for results. Two of the leading companies that currently offer clinical tumor genotyping are GenPath Diagnostics and Foundation Medicine.
GenPath Diagnostics is a leading diagnostic company and the exclusive licensee of the MGH SNaPshot assay, which is offered to the public through a clinician’s request under the name OnkoMatch
. Please visit their website
for more information.
Foundation Medicine offers a next-generation sequencing test that screens hundreds of cancer-related genes, under the name of FoundationOne.